Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
4.100
-0.230 (-5.31%)
At close: Jun 6, 2025, 4:00 PM
4.040
-0.060 (-1.46%)
After-hours: Jun 6, 2025, 6:02 PM EDT
Avalo Therapeutics Employees
Avalo Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 4 or 21.05% compared to the previous year.
Employees
23
Change (1Y)
4
Growth (1Y)
21.05%
Revenue / Employee
$19,174
Profits / Employee
$3,174,435
Market Cap
44.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AVTX News
- 10 days ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 5 weeks ago - Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewsWire
- 2 months ago - Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Benzinga
- 2 months ago - Avalo Reports 2024 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 months ago - Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 months ago - Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer - GlobeNewsWire